News & Events
Lupeng Presents the Latest Results of LP-118 at the 63rd ASH Annual Meeting
December 13, 2021: 2:45 PM (EST), Lupeng Pharmaceutical presented the latest data of its own proprietary LP-118, the next generation of Bcl-2 inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting. The title is "Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax (Abstract Number: 679)". Dr. Jennifer A. Woyach of Ohio State University, Dr. Deepa Sampath of the University of Texas MD Anderson Cancer Center, and Dr John C. Byrd of University of Cincinnati were the principal investigator of this oral presentation.
13 Nov 2021 17:00:00
Guangzhou Lupeng Pharmaceutical Company Ltd. Closes $35M Round in Pre-B Funding to Continue Clinical Trial and Expand Drug Pipeline
28 Jul 2021 02:00:00
Lupeng Pharmaceutical has been officially recognized as a “Potential Unicorn Enterprise in 2020” in Huangpu District and GDD
16 Jun 2021 01:00:00
Dr. Fenlai Tan was Invited to GBA (Guangzhou) Biomedical Innovator Summit as a Key Note Speaker
13 May 2021 01:00:00